



SCIENTIFIC
REGISTRY OF
TRANSPLANT
RECIPIENTS

Variation in Cost of Death and Graft Failure Across All Solid Organs

MA Schnitzler,^{1,2} M Skeans,² KL Lentine,¹ D Axelrod,³ H
Randall¹

¹Saint Louis University, St. Louis, United States; ²Scientific Registry of
Transplant Recipients, Minneapolis, United States; ³Lahey Clinic,
Burlington, United States

Disclosures

Mark A. Schnitzler, PhD
Professor of surgery
Saint Louis University, St. Louis MO, U.S.A.

I have no financial relationships to disclose within the past 12 months relevant to my presentation. The ACCME defines 'relevant' financial relationships as financial relationships in any amount occurring within the past 12 months that create a conflict of interest.

My presentation does not include discussion of off-label or investigational use.

I do not intend to reference unlabeled/unapproved uses of drugs or products in my presentation.

This work was supported wholly or in part by HRSA contract HSH250201500009C. The content is the responsibility of the authors alone and does not necessarily reflect the views or policies of the Department of HHS, nor does mention of trade names, commercial products, or organizations imply endorsement by the U.S. Government.



Background

- Economic outcomes are increasingly considered along with clinical efficacy to guide choice of alternative therapies.
- However, limited information has been available describing the cost implications of the major events we most seek to reduce, death and graft failure, for organs other than kidney.

Aim

Document and compare the cost impact of death and graft failure for all solid organ transplant modalities in the US using Medicare data linked to the national transplant registry.


Study Design

- Data for all solid organ transplant recipients between 2008 and 2013 identified from the Scientific Registry of Transplant Recipients (SRTR) were linked with payment data from Medicare for all recipients with Medicare as primary payer at the time of transplant.
- Variation in Medicare payment correlates with provider cost due to the structure of Medicare reimbursement. Private payer costs are likely proportionally higher.


Medicare Primary Sample (2008-2013)

- Kidney 57,279
- Pancreas 2940
- Liver 6991
- Intestine 71
- Heart 3135
- Lung 3118


Medicare Coverage by Age: Kidney




Medicare Coverage by Age: Lung




First-Year Per Patient (PP) Cost: Kidney




First- and Second-Year PP Cost: Kidney




First- and Second-Year PP Cost: Pancreas




First- and Second-Year PP Cost: Liver




First- and Second-Year PP Cost: Lung



First- and Second-Year PP Cost: Heart



First-Year PP Cost of Death



Conclusions

- The costs of death and graft failure are large following solid organ transplant.
- This information is essential for determining the value of interventions designed to avoid these adverse outcomes.
- We hope these data can facilitate efforts to improve outcomes across all types of solid organ transplants.
- Google: "SRTR ADR."

OPTN/SRTR 2016 Annual Data Report: Economics

M. A. Schnitzler^{1,2}, M. A. Skeans¹, D. A. Axelrod³, K. L. Lentine²,
H. B. Randall², J. J. Snyder^{1,4}, A. K. Israni^{1,4,5}, B. L. Kasiske^{1,5}

¹ Scientific Registry of Transplant Recipients, Minneapolis Medical Research Foundation, Minneapolis, MN

² Department of Surgery, Saint Louis University School of Medicine, St. Louis, MO

³ Department of Surgery, Lahey Hospital and Medical Center, Burlington, MA

⁴ Department of Epidemiology and Community Health, University of Minnesota, Minneapolis, MN

⁵ Department of Medicine, Hennepin County Medical Center, University of Minnesota, Minneapolis, MN

Abstract

Medicare costs vary for solid organ transplant recipients by outcome: survival with graft function, survival with graft failure, and death. Average per-person per-year reimbursement was \$75 thousand for kidney recip-